NextBioMedical Co

NextBioMedical Co Rule of 40

The Rule of 40 of NextBioMedical Co (389650.KQ) as of Oct 23, 2026 is 68.30 %. In the previous year, Rule of 40 was 111.34 % — a change of -38.66% (lower).

Rule of 40

68.30 %

YoY

-38.66%

Last updated:

Rule of 40 of NextBioMedical Co is 2025 68.30 % . Rule of 40 of NextBioMedical Co was 2024 111.34 % . It decreases by -38.66% lower compared to the previous year.

The NextBioMedical Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2022
-150.67 KRW
Jan 1, 2023
-82.06 KRW
Jan 1, 2024
111.34 KRW
Jan 1, 2025
68.30 KRW
The NextBioMedical Co Rule of 40 history
YEARRule of 40YoY
68.30 %-38.66%
111.34 %-235.68%
-82.06 %-45.54%
-150.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Rule of 40 of NextBioMedical Co is 68.30 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — NextBioMedical Co

All Key Metrics — NextBioMedical Co